MiNK Therapeutics, Inc. (INKT) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$11.03

From 52W high−25.40%

Volume5705.00

Market cap$54.09M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$11.03

From 52W high

−25.40%

Volume

5705.00

Market cap

$54.09M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.8x

P/E (TTM)

—

RSI (14)

52.0

MomentumView details →

1D Return

−1.76%

YTD Return

−1.08%

SummaryUpdated Jun 1, 2026

MiNK Therapeutics, Inc. (NASDAQ:INKT) is a clinical-stage biopharmaceutical company founded in 2017 and based in New York, New York. Originally incorporated as AgenTus Therapeutics, Inc., the company went public in October 2021 and operates as a subsidiary of Agenus Inc. MiNK specializes in developing innovative cancer immunotherapies using a unique type of immune cell called invariant natural killer T (iNKT) cells, positioning itself at the forefront of next-generation cell therapy development.

Ask drillr about MiNK Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.8x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

−3.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

80.98%

ROA (TTM)

−118.15%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+17.30%

FCF YoY

+99.49%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−1.03%

EBITDA YoY

−8.23%

MomentumView details →

1D Return

−1.76%

YTD Return

−1.08%

1Y Return

−15.61%

RSI (14)

52.0

vs 50D SMA

−2.40%

vs 200D SMA

−2.20%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

1.23x

Quick Ratio

1.23x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.62

EPS Surprise

−3.33%

Beats (12Q)

6/12

Next Q EPS Est

−$0.51

Avg Surprise (4Q)

−11.42%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−11.36M

Op. CF (TTM)

−6.83M

Next earningsNov 11, 2026 →

Latest newsMore news →

MiNK Therapeutics, Inc. announced that it will report its third-quarter 2026 results.2d ago

MiNK Therapeutics was selected to provide its agenT-797 iNKT cell therapy platform for the ARPA-H-funded BoSS program, which aims to move living medicines from cryogenic storage toward room temperature.36d ago

Similar companies

Kezar Life Sciences, Inc.KZR Werewolf Therapeutics, Inc.HOWL Apollomics, Inc.APLM Boundless Bio, Inc.BOLD Pliant Therapeutics, Inc.PLRX Oncolytics Biotech Inc.ONCY Find similar companies →

Latest newsMore news →

MiNK Therapeutics, Inc. announced that it will report its third-quarter 2026 results.2d ago MiNK Therapeutics was selected to provide its agenT-797 iNKT cell therapy platform for the ARPA-H-funded BoSS program, which aims to move living medicines from cryogenic storage toward room temperature.36d ago